GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

gamgertamig   Click here for help

GtoPdb Ligand ID: 14455

Synonyms: CM336 | OM-336 | OM336
Immunopharmacology Ligand
Compound class: Antibody
Comment: Gamgertamig (OM336, formerly CM336) is a dual BCMA (TNFRSF17)/CD3e monoclonal antibody of the T cell engager class. It is proposed to target the B cells that drive certain autoimmune diseases and B cell malignancies.
Peptide sequences for the heavy and light chains of both the CD3e and BCMA arms of gamgertamig are claimed in Keymed Biosciences' patent US20240002540A1 [1].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
Gamgertamig (OM336) has been advanced as a clinical candidate for the treatment of chronic autoimmune conditions (in particular those that result in autoimmune destruction of circulating blood cells) and multiple myeloma.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT07229144 OM336 in Seropositive Autoimmune Diseases Phase 1 Interventional Ouro Medicines
NCT07083960 OM336 in Autoimmune Cytopenias Phase 1 Interventional Ouro Medicines
NCT06900010 A Study to Evaluate CM336 in Adults with Autoimmune Bullous Disease Phase 1/Phase 2 Interventional Shandong First Medical University
NCT06799611 An Open, Exploratory Clinical Study of CM336 in the Treatment of Immune Thrombocytopenia Phase 2 Interventional Institute of Hematology & Blood Diseases Hospital, China
NCT07175493 A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia Phase 1/Phase 2 Interventional Keymed Biosciences Co.Ltd
NCT07181239 Study of CM336 in Relapsed or Refractory Multiple Myeloma Patients Phase 3 Interventional Keymed Biosciences Co.Ltd